Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P49802
UPID:
RGS7_HUMAN
Alternative names:
-
Alternative UPACC:
P49802; Q5T3H4; Q8TD66; Q8TD67; Q8WW09; Q9UNU7; Q9Y6B9
Background:
Regulator of G-protein signaling 7 (RGS7) is a critical component of the RGS7-GNB5 complex, pivotal in regulating G protein-coupled receptor signaling pathways. It inhibits signal transduction by enhancing the GTPase activity of G protein alpha subunits, leading to their inactive GDP-bound form. RGS7 is implicated in synaptic vesicle exocytosis and modulates potassium channels activated by GNAO1 in response to muscarinic acetylcholine receptor M2/CHRM2 signaling.
Therapeutic significance:
Understanding the role of Regulator of G-protein signaling 7 could open doors to potential therapeutic strategies.